<DOC>
	<DOCNO>NCT02766790</DOCNO>
	<brief_summary>TA-65 MD® pure , natural , plant-based compound help maintain rebuild telomere . A telomere region repetitive DNA end chromosome , protect end chromosome deterioration . They shorten cell division eventually signal irreversible state growth arrest know cellular senescence . The length person 's telomere indicator overall health status ; short telomere associate cellular age dysfunction .</brief_summary>
	<brief_title>Effect TA-65MD Healthy Volunteers</brief_title>
	<detailed_description>The purpose clinical study evaluate effect TA-65 MD® telomere length immunosenescence subject 9 month twice daily TA-65 MD® administration , compare placebo . TA Sciences develop different dos TA-65® . The study intend determine effect four different dos TA-65 MD® term biomarkers , telomere length overall health sleep status .</detailed_description>
	<criteria>1 . Healthy adult male female , base medical history current status . 2 . Ages 4575 year age ( inclusive time Screening ) . 3 . Voluntary consent method completion sign ICF ( informed consent form ) . 4 . BMI 18 40 kg/m2 ( inclusive time Screening ) . 5 . Subjects able understand comply protocol requirement , instruction , protocolstated restriction . 1 . History presence clinically significant cardiovascular , pulmonary , respiratory , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease , opinion Investigator , would jeopardize safety subject impact validity study result . 2 . History HIV , Hepatitis B , Hepatitis C. 3 . Females pregnant , plan become pregnant study , breastfeed . 4 . Recent current medical condition might significantly affect pharmacodynamic response compromise safety subject impact validity study result opinion Investigator . ( e.g. , condition require take diuretic medication and/or cardiac stimulant . ) 5 . Intake investigational product within 30 day prior screen visit . 6 . History allergic reaction study product ingredient ( ) comparable product opinion Investigator . 7 . History drug alcohol addiction abuse within 1 year prior Day 1 product administration end study ( EOS ) . 8 . Donation blood within 30 day plasma within 7 day , prior Day 1 product administration EOS . 9 . Intolerance venipuncture inability swallow capsule .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>